Effect of Basic Fibroblast Growth Factor on Xenogeneic Islets in Subcutaneous Transplantation—A Murine Model

Sin Yu Yang, Kai Chiang Yang, Shoichiro Sumi

研究成果: 雜誌貢獻文章

摘要

Background: Subcutaneous pockets provide an extrahepatic transplant site for islet grafting to treat type 1 diabetes. However, a hypoxic environment may cause central necrosis to islets and lead to graft failure. Our previous studies focused on a pre-treated subcutaneous site with basic fibroblast growth factor (bFGF)for the formation of vascular bed. In addition to neovascularization, bFGF was also shown to protect islets against oxidative stress and chemical-induced damage in vitro. Accordingly, we propose that subcutaneous islet transplantation with a bFGF-slow releasing device simultaneously can improve islet survival in vivo. Methods: A bFGF-impregnated collagen sheet was implanted in the right back of a streptozotocin-induced diabetic mouse for neovascularization. After 10 days, the sheet was removed and the rat islet-embedding gel within the immune-isolation device was transplanted (2-time operation [OP]). In another group, the diabetic mice received bFGF-impregnated gel with rat islets within the immune-isolation device simultaneously (1-time OP). Results: Diabetic mice in 2-time OP group experienced a decrease in their non-fasting blood glucose level for a period of 10 days, and the glucose levels were lower than those of untreated diabetic mice post-implantation. However, the mice in the 1-time OP group remained hyperglycemic post-operation and showed no improvements in body weight or the area under curve in intraperitoneal glucose tolerance test. Furthermore, mice in the 2-time OP had relatively higher serum insulin levels with improved renal and metabolic biomarkers. Conclusion: Our findings suggest that bFGF had no beneficial effect on a 1-time operation in subcutaneous islet transplantation.

原文英語
頁(從 - 到)1458-1462
頁數5
期刊Transplantation Proceedings
51
發行號5
DOIs
出版狀態已發佈 - 六月 1 2019

指紋

Fibroblast Growth Factor 2
Islets of Langerhans Transplantation
Equipment and Supplies
Gels
Transplants
Glucose Tolerance Test
Streptozocin
Type 1 Diabetes Mellitus
Area Under Curve
Blood Vessels
Blood Glucose
Oxidative Stress
Necrosis
Collagen
Biomarkers
Body Weight
Insulin
Kidney
Glucose
Serum

ASJC Scopus subject areas

  • Surgery
  • Transplantation

引用此文

Effect of Basic Fibroblast Growth Factor on Xenogeneic Islets in Subcutaneous Transplantation—A Murine Model. / Yang, Sin Yu; Yang, Kai Chiang; Sumi, Shoichiro.

於: Transplantation Proceedings, 卷 51, 編號 5, 01.06.2019, p. 1458-1462.

研究成果: 雜誌貢獻文章

@article{672a982c2fc04cae97bdd4fd8b7fd719,
title = "Effect of Basic Fibroblast Growth Factor on Xenogeneic Islets in Subcutaneous Transplantation—A Murine Model",
abstract = "Background: Subcutaneous pockets provide an extrahepatic transplant site for islet grafting to treat type 1 diabetes. However, a hypoxic environment may cause central necrosis to islets and lead to graft failure. Our previous studies focused on a pre-treated subcutaneous site with basic fibroblast growth factor (bFGF)for the formation of vascular bed. In addition to neovascularization, bFGF was also shown to protect islets against oxidative stress and chemical-induced damage in vitro. Accordingly, we propose that subcutaneous islet transplantation with a bFGF-slow releasing device simultaneously can improve islet survival in vivo. Methods: A bFGF-impregnated collagen sheet was implanted in the right back of a streptozotocin-induced diabetic mouse for neovascularization. After 10 days, the sheet was removed and the rat islet-embedding gel within the immune-isolation device was transplanted (2-time operation [OP]). In another group, the diabetic mice received bFGF-impregnated gel with rat islets within the immune-isolation device simultaneously (1-time OP). Results: Diabetic mice in 2-time OP group experienced a decrease in their non-fasting blood glucose level for a period of 10 days, and the glucose levels were lower than those of untreated diabetic mice post-implantation. However, the mice in the 1-time OP group remained hyperglycemic post-operation and showed no improvements in body weight or the area under curve in intraperitoneal glucose tolerance test. Furthermore, mice in the 2-time OP had relatively higher serum insulin levels with improved renal and metabolic biomarkers. Conclusion: Our findings suggest that bFGF had no beneficial effect on a 1-time operation in subcutaneous islet transplantation.",
author = "Yang, {Sin Yu} and Yang, {Kai Chiang} and Shoichiro Sumi",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.transproceed.2019.01.135",
language = "English",
volume = "51",
pages = "1458--1462",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Effect of Basic Fibroblast Growth Factor on Xenogeneic Islets in Subcutaneous Transplantation—A Murine Model

AU - Yang, Sin Yu

AU - Yang, Kai Chiang

AU - Sumi, Shoichiro

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: Subcutaneous pockets provide an extrahepatic transplant site for islet grafting to treat type 1 diabetes. However, a hypoxic environment may cause central necrosis to islets and lead to graft failure. Our previous studies focused on a pre-treated subcutaneous site with basic fibroblast growth factor (bFGF)for the formation of vascular bed. In addition to neovascularization, bFGF was also shown to protect islets against oxidative stress and chemical-induced damage in vitro. Accordingly, we propose that subcutaneous islet transplantation with a bFGF-slow releasing device simultaneously can improve islet survival in vivo. Methods: A bFGF-impregnated collagen sheet was implanted in the right back of a streptozotocin-induced diabetic mouse for neovascularization. After 10 days, the sheet was removed and the rat islet-embedding gel within the immune-isolation device was transplanted (2-time operation [OP]). In another group, the diabetic mice received bFGF-impregnated gel with rat islets within the immune-isolation device simultaneously (1-time OP). Results: Diabetic mice in 2-time OP group experienced a decrease in their non-fasting blood glucose level for a period of 10 days, and the glucose levels were lower than those of untreated diabetic mice post-implantation. However, the mice in the 1-time OP group remained hyperglycemic post-operation and showed no improvements in body weight or the area under curve in intraperitoneal glucose tolerance test. Furthermore, mice in the 2-time OP had relatively higher serum insulin levels with improved renal and metabolic biomarkers. Conclusion: Our findings suggest that bFGF had no beneficial effect on a 1-time operation in subcutaneous islet transplantation.

AB - Background: Subcutaneous pockets provide an extrahepatic transplant site for islet grafting to treat type 1 diabetes. However, a hypoxic environment may cause central necrosis to islets and lead to graft failure. Our previous studies focused on a pre-treated subcutaneous site with basic fibroblast growth factor (bFGF)for the formation of vascular bed. In addition to neovascularization, bFGF was also shown to protect islets against oxidative stress and chemical-induced damage in vitro. Accordingly, we propose that subcutaneous islet transplantation with a bFGF-slow releasing device simultaneously can improve islet survival in vivo. Methods: A bFGF-impregnated collagen sheet was implanted in the right back of a streptozotocin-induced diabetic mouse for neovascularization. After 10 days, the sheet was removed and the rat islet-embedding gel within the immune-isolation device was transplanted (2-time operation [OP]). In another group, the diabetic mice received bFGF-impregnated gel with rat islets within the immune-isolation device simultaneously (1-time OP). Results: Diabetic mice in 2-time OP group experienced a decrease in their non-fasting blood glucose level for a period of 10 days, and the glucose levels were lower than those of untreated diabetic mice post-implantation. However, the mice in the 1-time OP group remained hyperglycemic post-operation and showed no improvements in body weight or the area under curve in intraperitoneal glucose tolerance test. Furthermore, mice in the 2-time OP had relatively higher serum insulin levels with improved renal and metabolic biomarkers. Conclusion: Our findings suggest that bFGF had no beneficial effect on a 1-time operation in subcutaneous islet transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85066281014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066281014&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2019.01.135

DO - 10.1016/j.transproceed.2019.01.135

M3 - Article

C2 - 31155179

AN - SCOPUS:85066281014

VL - 51

SP - 1458

EP - 1462

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -